BERNARDI, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.490
AS - Asia 3.929
EU - Europa 1.979
SA - Sud America 594
Continente sconosciuto - Info sul continente non disponibili 125
AF - Africa 102
OC - Oceania 5
Totale 14.224
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.338
SG - Singapore 1.181
HK - Hong Kong 813
CN - Cina 676
VN - Vietnam 454
BR - Brasile 428
GB - Regno Unito 352
IT - Italia 326
BD - Bangladesh 298
SE - Svezia 296
FI - Finlandia 261
RU - Federazione Russa 175
DE - Germania 118
KR - Corea 113
BG - Bulgaria 92
CA - Canada 79
FR - Francia 73
IN - India 67
AR - Argentina 66
NL - Olanda 47
JP - Giappone 42
IQ - Iraq 41
AE - Emirati Arabi Uniti 37
ID - Indonesia 37
ZA - Sudafrica 37
MX - Messico 34
PL - Polonia 31
UA - Ucraina 30
IE - Irlanda 28
TR - Turchia 27
AT - Austria 25
BE - Belgio 23
PK - Pakistan 23
CO - Colombia 22
ES - Italia 20
CL - Cile 18
EC - Ecuador 17
LT - Lituania 14
MY - Malesia 14
VE - Venezuela 14
CZ - Repubblica Ceca 13
DZ - Algeria 13
EG - Egitto 13
SA - Arabia Saudita 13
PY - Paraguay 12
KE - Kenya 10
UZ - Uzbekistan 10
IR - Iran 9
KZ - Kazakistan 9
MA - Marocco 9
IL - Israele 8
PH - Filippine 8
AZ - Azerbaigian 7
CR - Costa Rica 7
ET - Etiopia 7
JO - Giordania 7
NO - Norvegia 7
RO - Romania 7
UY - Uruguay 7
DO - Repubblica Dominicana 6
PE - Perù 6
TN - Tunisia 6
CH - Svizzera 5
DK - Danimarca 5
HN - Honduras 5
NP - Nepal 5
RS - Serbia 5
AU - Australia 4
BO - Bolivia 4
BY - Bielorussia 4
GT - Guatemala 4
JM - Giamaica 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
HU - Ungheria 3
KG - Kirghizistan 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
OM - Oman 3
SV - El Salvador 3
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
LV - Lettonia 2
MK - Macedonia 2
NI - Nicaragua 2
PR - Porto Rico 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
CD - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
Totale 14.086
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.168
Ashburn 885
Hong Kong 807
Singapore 769
Fairfield 552
Chandler 548
San Jose 297
Helsinki 255
Nyköping 255
London 220
Woodbridge 208
Houston 199
Wilmington 195
Seattle 166
Cambridge 159
Beijing 149
Ann Arbor 148
Los Angeles 141
Ho Chi Minh City 140
New York 137
Council Bluffs 123
Hanoi 116
The Dalles 116
San Diego 114
Seoul 109
Chicago 107
Sofia 91
Princeton 90
Buffalo 61
Hefei 60
Milan 56
Orem 53
Salt Lake City 50
Moscow 47
São Paulo 45
Shanghai 41
Southend 41
Dallas 38
Jersey City 34
Bremen 33
Tokyo 29
Dearborn 28
North Bergen 28
Da Nang 27
Phoenix 27
Dublin 26
Brussels 23
Johannesburg 23
Rome 23
Tampa 23
Toronto 23
Haiphong 22
Jakarta 22
Warsaw 22
Chennai 21
Redondo Beach 21
Reading 20
Frankfurt am Main 18
Amsterdam 17
San Francisco 17
Atlanta 15
Brooklyn 15
Bologna 14
Elk Grove Village 14
Mexico City 14
Miano 14
Rio de Janeiro 14
Groningen 13
Lauterbourg 13
Montreal 13
Paris 13
Vienna 13
Biên Hòa 12
Brno 12
Denver 12
Detroit 12
Manchester 12
Stockholm 12
Jacksonville 11
Norwalk 11
Des Moines 10
Falkenstein 10
Nairobi 10
Vancouver 10
Baghdad 9
Belo Horizonte 9
Buenos Aires 9
Charlotte 9
Curitiba 9
Dhaka 9
Kilburn 9
Miami 9
Modena 9
Newark 9
Nuremberg 9
Philadelphia 9
Pittsburgh 9
Santiago 9
Sterling 9
Augusta 8
Totale 9.725
Salva come PNG Salva come JPEG
Nome #
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity 365
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 323
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 315
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 288
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 278
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation 259
Adaptive response in Hepatitis B virus infection 239
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 229
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 220
Alcohol and viral hepatitis: a mini-review 218
C-11 Acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma 210
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 209
CD 133+ stem cells for the treatment of end stage liver disease 208
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 204
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 201
Chronic hepatitis B: Are we close to a cure? 199
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 193
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 190
Characterization of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver 184
MARS and Prometheus: our clinical experience in acute chronic liver failure 182
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 180
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned 179
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 178
Stem cell mobilization and collection in patients with liver cirrhosis 177
Liver transplantation for patients with alcoholic liver disease: an open question 176
In vitro effect of indomethacin and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C 175
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 175
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 172
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 170
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B 165
Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy 163
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance 161
Bone marrow derived stem cells for the treatment of end-stage liver disease 159
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naive and non-responder patients on a stable immunosuppressive regimen 159
Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection 158
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels 158
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? 158
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool 157
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival 156
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection 154
Relationship between hepatic hemodynamics assessed by Doppler ultrasound and liver stiffness 153
Ketoprofen, peginterferon-alpha2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study 151
Genetic variability of hepatitis C virus in HBV/HCV co-infection and HCV single-infection 151
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B 151
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? 149
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 148
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report 147
Trattamento dell’epatopatia alcolica 144
Hepatitis B virus and immune response 143
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation 142
Serum hepatitis B surface antigen monitoring in long-term Lamivudine-treated hepatitis B virus patients 142
Review article: Alcoholic liver disease - Pathophysiological aspects and risk factors 142
Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C 140
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study 139
Hepatitis C in the elderly: a multicenter cross-sectional study by the Italian Association for the Study of the Liver 137
Genetic heterogeneity of hepatitis C virus in HBV/HCV co-infection 136
Hepatocellular carcinoma in patients with cryptogenic cirrhosis 136
The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis 133
Immunological modifications during treatment with thymosin alpha 1 plus antiviral therapy in chronic hepatitis C 132
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 132
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 130
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case controlled study 130
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin 129
Role of Contrast-Enhanced Ultrasonography in Primary Hepatic Lymphoma 129
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 128
Virological analysis, genotypes and mutational patterns of the HBV pre-core/core gene in HBV/HCV-related hepatocellular carcinoma 127
Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant 124
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 122
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study 120
Vitamins in the treatment of chronic viral hepatitis 115
Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study 115
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial 114
Post-transplantation lymphoproliferative disorders in liver transplanted patients: a report of four cases 112
MUTATIONAL ANALYSIS OF THE HBV PRE-CORE/CORE GENE IN HBV/HCV-RELATED HEPATOCELLULAR CARCINOMA 110
Stem cells for end stage liver disease: How far have we got? 110
Tenofovir-induced Fanconi syndrome in a patient with chronic hepatitis B monoinfection 109
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance 109
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS) 107
Effect of liver transplantation on tuftsin activity and phagocytic activity of neutrophyl granulocytes in patients with liver cirrhosis 107
Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses 106
Cryoglobulinemia in elderly patients with HCV-related chronic hepatitis 104
ECHO-COLOUR-DOPPLER CHARACTERIZATION OF CIRRHOTIC PATIENTS RESPONDERS AND NON-RESPONDERS TO NADOLOL AS PRIMARY PROPHYLAXIS 103
Hepatic artery stenosis in liver transplanted patients treated with pegylated Interferon alpha-2b and Ribavirin 103
Sustained and focused HBV-nucleocapsid-specific T cell immunity in liver transplant recipients compared to individuals with chronic and self-limited HBV infection 99
OUTCOME OF LIVER TRANSPLANT FOR ALCOHOLIC LIVER DISEASE 98
In portal hypertensive cirrhotic patients abdominal porto-systemic collaterals at ultrasound identify a group of patients at high risk of death 98
Evolution of hepatitis C vitus non structural 5A gene (NS5A) in the progression of liver disease to hepatocellular carcinoma 98
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 97
PEGYLATED INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF RECURRENT HCV INFECTION AFTER LIVER TRANSPLANTATION 95
Vitamin E as treatment for chronic viral hepatitis: is it time to perform large clinical trials? 84
Totale 14.224
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.484 257 134 48 25 11 86 90 85 207 185 193 163
2022/20231.378 188 174 101 137 160 225 11 126 174 4 44 34
2023/2024778 26 47 33 79 217 22 44 122 28 18 28 114
2024/20253.171 117 23 6 238 839 492 116 252 327 178 221 362
2025/20265.940 260 114 387 630 831 439 716 441 576 581 484 481
2026/2027231 231 0 0 0 0 0 0 0 0 0 0 0
Totale 14.224